Tablet Dissolution Failure: Root Causes, Troubleshooting and CAPA in Pharmaceutical Manufacturing
Tablet dissolution failure is a critical quality issue in pharmaceutical manufacturing. It may affect batch release, product performance, investigations, and regulatory compliance. Understanding the relationship between formulation, granulation, compression, coating, and dissolution testing is essential for identifying the actual root cause.
In this guide, we will discuss the common causes of low tablet dissolution, a systematic troubleshooting approach, manufacturing process variables, laboratory investigations, and Corrective and Preventive Action (CAPA).
1. What Is Tablet Dissolution?
Dissolution is the process by which an active pharmaceutical ingredient (API) enters solution from a dosage form under specified test conditions.
Dissolution testing is used to evaluate drug release from tablets and capsules. The applicable method, apparatus, medium, speed, sampling time, and acceptance criteria depend on the approved product specification and relevant compendial requirements.
A dissolution failure occurs when test results do not meet the applicable acceptance criteria.
Important: A dissolution result should always be evaluated against the approved analytical method and product-specific specification. There is no single dissolution limit suitable for every tablet.
2. Common Causes of Tablet Dissolution Failure
A. API-related factors
The physical and chemical properties of the API can influence drug release.
Important factors include:
- Particle size distribution and particle morphology.
- Polymorphic form and crystallinity.
- Aqueous solubility and wettability.
- API-excipient compatibility.
- API variability between suppliers or batches.
Investigation: Compare the failing batch with a previously acceptable batch using approved specifications, supplier information, and relevant analytical data.
B. Granulation-related factors
Wet granulation can influence tablet porosity, disintegration, and drug release.
Possible causes include:
- Excessive granulation liquid.
- Overgranulation or excessive granule densification.
- Inappropriate binder concentration.
- Inadequate or excessive drying.
- Changes in granule particle size distribution.
- Poor distribution of the API within the granules.
Investigation: Review granulation endpoint, binder preparation, liquid addition, impeller and chopper settings, drying profile, LOD, and granule size distribution.
Do not assume that increasing binder or reducing binder will always improve dissolution. The correct adjustment depends on the formulation and the identified mechanism.
C. Compression-related factors
Compression can influence tablet hardness, porosity, water penetration, and disintegration.
Common factors include:
- Excessive compression force.
- Increased tablet hardness or reduced porosity.
- Excessive dwell time or changes in compression settings.
- Changes in tablet thickness and weight.
- Excessive lubrication or prolonged lubricant blending.
Investigation: Compare compression force, hardness, thickness, disintegration time, friability, and dissolution results with historical batch data.
A harder tablet does not automatically fail dissolution. The relationship must be demonstrated through appropriate data.
D. Lubrication-related factors
Magnesium stearate is hydrophobic. Excessive concentration or prolonged blending may reduce powder wettability and affect tablet performance in some formulations.
Review:
- Lubricant concentration.
- Lubricant grade and particle characteristics.
- Lubrication time and blender speed.
- Order of addition.
- Other excipients that may affect wetting or disintegration.
Any formulation or process change should be supported by development knowledge and evaluated through the appropriate change-control process.
E. Coating-related factors
For film-coated tablets, coating composition and process conditions may affect water penetration or drug release.
Potential factors include:
- Excessive coating weight gain.
- Changes in polymer or plasticizer concentration.
- Inappropriate coating process conditions.
- Inadequate control of curing or drying, where relevant.
- Changes in coating integrity or film properties.
For immediate-release products, verify that the coating is not unintentionally delaying disintegration or dissolution. For modified-release products, evaluate coating variables against the intended release mechanism.
3. Troubleshooting Table for Low Tablet Dissolution
Observation| Areas to investigate
Low dissolution with prolonged disintegration| Tablet porosity, compression force, binder level, disintegrant performance
Low dissolution despite acceptable disintegration| API solubility, particle size, wettability, analytical method and medium
Dissolution worsens after lubrication| Lubricant concentration, blending time, lubricant distribution
Dissolution worsens after coating| Coating weight gain, film properties, process conditions
High variability between vessels| Sampling, deaeration, apparatus condition, medium preparation, dosage-unit variability
One batch fails while previous batches pass| API and excipient lots, process parameters, equipment changes, operator and environmental records
These observations are investigation leads, not proof of root cause. More than one factor may contribute to the failure.
4. Step-by-Step Investigation of Dissolution Failure
Step 1: Verify the laboratory result
Review the approved analytical method, calculations, instrument suitability, reference standards, medium preparation, sampling procedure, and equipment records.
Check whether the method was followed as written and whether any documented laboratory event could have affected the result.
Do not repeat testing simply to obtain a passing result. Retesting and resampling must follow approved procedures and a scientifically justified investigation.
Step 2: Review disintegration and physical tablet properties
Compare dissolution results with disintegration time, hardness, thickness, friability, and tablet weight.
These results help determine whether the problem may be associated with tablet structure or drug release independent of disintegration.
Step 3: Review manufacturing records
Examine the batch manufacturing record and relevant equipment logs for:
- Granulation endpoint and liquid addition.
- Drying time, temperature, and LOD.
- Milling and granule size distribution.
- Lubrication time and blending conditions.
- Compression force and hardness trends.
- Coating parameters and weight gain.
- Any deviations, adjustments, or equipment interruptions.
Compare the failing batch with successful batches, while accounting for differences in raw materials, formulation, and equipment.
Step 4: Evaluate the API and excipients
Review material release results, supplier changes, certificates of analysis, particle size data where applicable, and storage conditions.
Investigate whether any material attribute could plausibly explain the observed dissolution pattern.
Step 5: Establish the root cause
Use appropriate investigation tools such as:
- Fishbone diagram.
- 5 Whys analysis.
- Process trend analysis.
- Comparison of failing and passing batches.
- Scientifically designed experiments, where justified.
A root cause should be supported by evidence. A plausible explanation alone is not sufficient.
5. CAPA for Dissolution Failure
Corrective and Preventive Action should address the demonstrated cause rather than merely the failed result.
Example:
- Problem: A tablet batch fails the approved dissolution specification.
- Initial action: Place the affected batch under the applicable quality hold and initiate the formal investigation.
- Investigation: Review laboratory data, manufacturing records, material attributes, and historical trends.
- Root cause: Establish only after reviewing and evaluating the available evidence.
- Corrective action: Implement the scientifically justified correction under approved quality procedures.
- Preventive action: Revise controls, training, monitoring, or procedures where the investigation demonstrates a need.
- Effectiveness check: Define measurable acceptance criteria and review subsequent relevant data.
The batch disposition must be decided through the authorized quality system. A passing repeat test alone does not establish that the original failure was invalid.
6. How to Prevent Future Dissolution Failures
A robust prevention strategy includes:
1. Maintaining appropriate controls over API and excipient attributes.
2. Establishing scientifically justified granulation and drying endpoints.
3. Monitoring compression force and relevant tablet properties.
4. Controlling lubricant concentration and blending time.
5. Evaluating coating parameters against the intended drug-release mechanism.
6. Trending dissolution results alongside disintegration and manufacturing parameters.
7. Maintaining calibrated equipment and a suitable laboratory testing environment.
8. Applying formal deviation, CAPA, and change-control procedures.
The goal is to understand and control the process rather than make repeated adjustments after a failure occurs.
7. Regulatory References and Further Reading
Consult the current approved product specification, applicable pharmacopeial requirements, and relevant regulatory guidance when conducting an investigation.
Useful official resources include:
- "FDA: Data Integrity and Compliance With Drug CGMP" (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers)
- "FDA: Questions and Answers on CGMP Requirements" (https://www.fda.gov/drugs/pharmaceutical-quality-resources/qa-cgmp-requirements)
- "Google Search Central: Creating Helpful, Reliable, People-First Content" (https://developers.google.com/search/docs/fundamentals/creating-helpful-content)
Frequently Asked Questions
1. What are the common causes of low tablet dissolution?
Common investigation areas include API solubility and particle properties, granulation conditions, compression, lubrication, coating, and laboratory testing variables. The actual cause must be established for the specific product.
2. Can high tablet hardness cause dissolution failure?
It can contribute in some formulations by reducing porosity and slowing liquid penetration. However, hardness alone does not establish the cause; disintegration and dissolution data should be evaluated together.
3. Can magnesium stearate affect dissolution?
Yes. Depending on the formulation, concentration, grade, and blending conditions, magnesium stearate may affect wettability and drug release.
4. Does acceptable disintegration guarantee acceptable dissolution?
No. Disintegration and dissolution measure different properties. A tablet may disintegrate within its specified limit but still fail the dissolution requirement.
5. What is the correct CAPA for dissolution failure?
CAPA must be based on the documented root cause. It may involve material controls, manufacturing parameters, analytical controls, procedures, training, or process validation, depending on the evidence.
Conclusion
Tablet dissolution failure should be investigated systematically across laboratory testing, raw materials, formulation, granulation, compression, lubrication, and coating.
A science-based investigation supported by manufacturing records, comparative data, and an effective CAPA system helps improve product consistency and prevent recurrence.
Disclaimer: This article is intended for pharmaceutical industry education. Product-specific decisions must follow approved specifications, validated methods, applicable regulations, and authorized quality procedures.
